Pulmonary Arterial Hypertension (PAH) Industry
Description
Wiseguyreports.Com Adds “Pulmonary Arterial Hypertension (PAH) -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database
Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension (PH) condition, which means high blood pressure in the lungs. Many diseases such as obstructive sleep apnea (OSA), lung diseases, diastolic heart failure and diseases of the left heart can cause the pressures in the pulmonary arteries to elevate but is not pulmonary arterial hypertension. PAH is a life threatening disease characterized by an increase in pulmonary vascular resistance that eventually leads to death. It is a rare disease, affects about 15-70 people per million in the U.S. The symptoms of PAH are difficult to diagnose as the symptoms are common to other diseases.
Pulmonary arterial hypertension is a severe condition and there is no cure to PAH at present time. Many treatments are available to improve symptoms, quality of life and to keep the condition under control. There are currently four classes of drugs approved for the treatment of PAH and 13 approved products are available for PAH in the market across these four drug classes.
Request For Sample Report @ https://www.wiseguyreports.com/sample-request/3328272-global-pulmonary-arterial-hypertension-pah-market-industry-analysis
The United States is the main contributor to the PAH market with the development of new therapies and increasing cases of pulmonary arterial hypertension. The U.S. has great potential in the years ahead with rising awareness about treatment options of PAH.
The global PAH market is expected to grow in the future due to increasing ageing population, rise in healthcare expenditure, growing women population, increase in obese population and high unmet needs. Key trends of this market include increasing number of cardiovascular diseases, rising government support, and consumption of junk food. However, there are some factors which can hinder the growth of the market which includes patent expiration, high cost and lack of awareness.
The report “Global Pulmonary Arterial Hypertension Market: Industry Analysis & Outlook (2020-2024)” by WGR provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering
The United States and Europe region along with the global market. The report profiles the key players in the market including Johnson & Johnson, Gilead Sciences, United Therapeutics and GlaxoSmithKline.
Table of Content
1. Market Overview
1.1 Pulmonary Arterial Hypertension
1.2 Types of PAH
1.3 Causes and Risk Factors of PAH
1.4 Symptoms
1.5 Diagnosis
1.6 PAH Patient Grouping As Per WHO
1.7 Treatment
1.8 PAH Drugs Classification
1.9 Approved PAH Drugs
1.10 PAH Drugs In Development
2. Global Market Analysis
2.1 Global PAH Market by Value
2.2 Global PAH Market Forecast by Value
2.3 Global PAH Market by Drug Type
2.4 Global ERAs Drugs Market
2.4.1 Global ERAs Drugs Forecast Market by Value
2.4.2 Global Tracleer Revenue
2.4.3 Global Letairis Revenue
2.4.4 Global Opsumit Revenue
2.5 Global Prostacyclin Drugs Market
2.5.1 Global Prostacyclin Drugs Market Forecast by Value
2.5.2 Global Tyvaso Revenue
2.5.3 Global Remodulin Revenue
2.5.4 Global Veletri Revenue
2.5.5 Global Orentiram Revenue
2.6 Global PDE Drugs Market
2.6.1 Global PDE Drugs Market Forecast by Value
2.6.2 Global Revatio Revenue
2.6.3 Global Adrcica Revenue
2.7 Global sGC/Adempas Drugs Market
2.7.1 Global sGC Drugs Market Forecast by Value
2.8 Global Ralinepag Drug Revenue
3. Regional Market
3.1 The U.S.
3.1.1 The U.S. PAH Population Forecast
3.1.2 The U.S. PAH Incident Population Forecast
3.1.3 The U.S. PAH Population by WHO Patient Class Division
3.1.4 The U.S. WHO FC Patient Class Forecast
3.1.5 The U.S. Ralinepag Revenue
3.1.6 The U.S. Ralinepag Treated Patients
3.2 Europe
3.2.1 Europe PAH Population Forecast
3.2.2 Europe PAH Incident Population Forecast
3.2.3 Europe PAH Population by WHO Patient Class Division
3.2.4 Europe WHO FC Patient Class Forecast
3.2.5 Europe Ralinepag Revenue
3.2.6 Europe Ralinepag Treated Patients
Leave a Query @ https://www.wiseguyreports.com/enquiry/3328272-global-pulmonary-arterial-hypertension-pah-market-industry-analysis
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Healthcare Spending
4.1.2 Rising Ageing Population
4.1.3 Accelerating Economic Growth
4.1.4 Growing Female Population
4.1.5 Increase in Obese Population
4.1.6 Unmet Medical Needs
4.2 Trend & Developments
4.2.1 Growing Number of Cardiac Diseases
4.2.2 Growing Consumption of Fast Food
4.2.3 Favorable Government Support
4.3 Challenges
4.3.1 High Costs of Diagnosis and Treatment
4.3.2 Lack of Awareness
4.3.3 Expiry of Patents
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 Research and Development Expenditure Comparison
6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 United Therapeutics Corporation
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 GlaxoSmithKline Plc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Gilead Sciences
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3328272
Continued…
Contact Us: Sales@Wiseguyreports.com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)
